Recipharm Signs Partnership Agreement with Follicum
News Jun 04, 2015
Recipharm has announced that it has signed a partnership agreement with Follicum AB in preparation for a clinical trial of the drug candidate FOL-005.
Recipharm has been engaged to formulate and produce the product that will be used in the clinical trial. The engagement also includes developing and validating the analytical methods required.
“Preparations for the clinical study are well under way, and we have now established ties with partners that we feel confident in. Recipharm is successful in its field and has a strong track record. We look forward to the finished product, which is expected to be ready at the end of the year, in time for the launch of the clinical study,” says Jan Alenfall, CEO of Follicum.
“We have extensive experience in the development of pharmaceuticals for clinical trials and are very excited to be able to contribute to the development of this product,” says Maria Lundberg, General Manager of Recipharm in Solna.
Study Extends Potential of Personalized Cell-based ImmunotherapiesNews
New methods developed for the study could be applied to devise personalized, cell-based immunotherapies for epithelial ovarian cancer or other types of tumorsREAD MORE
Hope for Hot Flushes: New Class of Menopause Drugs Reduces SeverityNews
A new class of experimental drugs reduces hot flushes in menopausal women by almost three-quarters in just three days. The new analysis, published in the journal Menopause, also revealed sleep and concentration significantly improved in the three-day window.
Domainex Appoints Dr Bodo Spori as Head of Business Development for EuropeNews
Domainex Ltd, a privately-owned drug discovery services company, is pleased to announce the appointment of Dr Bodo Spori as Head of Business Development for Europe.READ MORE
Comments | 0 ADD COMMENT
World Congress on Clinical And Medical Microbiology
Sep 10 - Sep 11, 2018